



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 25.1.2022

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor
Plot No.62, G- Block, Opp Trident Hotel,
Bandra Kurla Complex, Bandra (E)
Mumbai — 400 098

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 25th January, 2022 - Reg.

Ref: Disclosure under Regulation 30 and 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015- Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Tuesday, 25th January, 2022 had inter-alia transacted the following items of business:

1. Approved the Un-audited Financial Results along with the segment results for the quarter and nine months ended 31st December, 2021.
2. Took note of the Limited Review Report on Un-audited Financial statements for the quarter and nine months ended 31st December, 2021.

We herewith enclose the following:

- A. Un-Audited financial Results along with the segment results for the quarter and nine months ended 31st December, 2021.
- B. Limited Review Report issued by statutory auditors of the company.

This is for your information and necessary records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited



B. Kumar

(B. Kumar)
Chief Financial Officer

The meeting Commenced at 4:00 PM
The Meeting Concluded at 5:00 PM

SIGACHI LABORATORIES LIMITED

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273,

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement of Un-Audited Financial Results For The Quarter and Nine Months Ended 31st December, 2021

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Nine Months ended		Year ended 31.03.2021
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Revenue from operations	44.27	100.87	113.78	220.40	269.29	347.61
2	Other income	14.53	6.77	9.36	29.80	22.76	38.09
3	Total Income (1+2)	58.80	107.64	123.14	250.20	292.05	385.70
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Change in Inventories	-	-	-	-	-	-
	d) Employee benefits expense	8.39	9.52	6.83	24.43	19.37	28.97
	e) Finance costs	-	-	-	-	-	-
	f) Depreciation and amortization expense	4.23	4.17	4.15	12.58	12.43	16.58
	g) Other expenses	3.14	3.38	2.03	10.17	6.86	26.50
	Total Expenses	15.76	17.07	13.01	47.18	38.66	72.05
5	Profit/(loss) before exceptional items and tax (3-4)	43.04	90.57	110.13	203.02	253.39	313.65
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(loss) before tax (5-6)	43.04	90.57	110.13	203.02	253.39	313.65
8	Tax expense						
	(a) Current tax	11.21	8.74	9.92	26.38	26.33	39.88
	(b) Deferred tax	(0.65)	(0.13)	0.01	(0.92)	(1.64)	(1.64)
	Total Tax Expense	10.56	8.61	9.93	25.46	24.69	38.24
9	Profit/(Loss) for the Period (7-8)	32.48	81.96	100.20	177.56	228.70	275.41
10	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or (loss)	(25.90)	74.88	170.36	143.72	383.75	414.42
	(b) Remeasurement gains/(losses) on defined benefit plans	-	-	-	-	-	0.03
	Tax on Items that will not be reclassified to profit or (loss)	-	-	-	-	-	(0.01)
	(c) Items that will be reclassified to profit or (loss)	-	-	-	-	-	-
	Total Other Comprehensive income	(25.90)	74.88	170.36	143.72	383.75	414.44
11	Total Comprehensive income (9+10)	6.58	156.84	270.56	321.28	612.45	689.85
12	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31	675.31	675.31
13	Other Equity	-	-	-	-	-	1,946.19
14	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))						
	(1) Basic	0.48	1.21	1.48	2.63	3.39	4.08
	(2) Diluted	0.48	1.21	1.48	2.63	3.39	4.08

Segment wise Revenue, Results and Capital Employed for the Quarter & Nine Months ended 31st December, 2021

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	30.50	30.00	29.00	80.50	76.50	116.50
	b) Investments	28.30	77.64	94.14	169.69	215.55	269.20
	Total	58.80	107.64	123.14	250.19	292.05	385.70
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net sales/Income from Operations	58.80	107.64	123.14	250.19	292.05	385.70
2	Segment Results Profit/ (Loss) before tax and finance costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	26.10	25.66	24.69	67.01	63.22	98.56
	b) Investments	28.30	77.64	94.14	169.69	215.55	269.20
	Total	54.40	103.30	118.83	236.70	278.77	367.76
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	11.36	12.73	8.70	33.68	25.38	54.11
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit Before Tax	43.04	90.57	110.13	203.02	253.39	313.65
3	Capital Employed						
	(Segment assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	619.55	600.51	618.40	619.55	618.40	620.95
	b) Investments	2,378.96	2,391.42	1,981.44	2,378.96	1,981.44	2,056.29
	Total	2,998.51	2,991.93	2,599.84	2,998.51	2,599.84	2,677.24

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 25th January, 2022.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Previous year/period figures have been recasted/regrouped/reclassified wherever necessary to make them comparable with current year/period figures.

By Order of the Board
for SIGACHI LABORATORIES LIMITED

Digitally signed by
Tunuguntla Raja Sekhar
Date: 2022.01.25
17:04:53 +05'30'

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 25.01.2022

INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To
The Board of Directors,
Sigachi Laboratories Limited,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sigachi Laboratories Limited** ("the company") for the quarter ended 31st December, 2021 and year to date results for the period from 1st April, 2021 to 31st December, 2021, ("the statement") being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind As 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these interim financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the interim financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant SEBI Circulars including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 25.01.2022
Place : Hyderabad



For Niranjana & Narayan
Chartered Accountants
FRN: 005899S

M. Niranjana
(M. Niranjana)
Partner

Membership No. 029552
Udin: 22029552AAAABB5561